Barclays raised the firm’s price target on Humana (HUM) to $245 from $234 and keeps an Equal Weight rating on the shares. The firm sees managed ...

Humana trades near fair value, reflecting a mixed profit outlook and Medicare Advantage uncertainties. Click here to read an analysis of HUM stock now.

HUM sits at a crossroads as Medicare Advantage pressures cap near-term upside, but resilience versus peers argues for ...

Humana stock was falling after the healthcare insurer announced the retirement of its current insurance president and reiterated guidance for this year. Humana shares were down 2.5% in premarket ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $170.0 to $360.0 for Humana over the last 3 months.

Humana is ramping up its focus on primary care. The insurer plans to shell out between $450 million and $550 million to buy the first group of senior-focused primary care centers it built through a ...

Humana Tuesday reported $1.2 billion in 2024 profits that included a $693 million fourth quarter loss as the health insurer exits unprofitable Medicare Advantage markets for 2025, the company ...

Hospitals and health systems continue to sever ties with certain Medicare Advantage plans heading into 2026, citing persistent frustrations with prior authorization denials and slow reimbursement from ...

Humana's margins have declined due to rising policy benefits, high medical loss ratios, and increased utilization ...

Early prescription refills by mail-order pharmacies cost Medicare and patients $3 billion over two years, from 2021–2023, according to a report by The Wall Street Journal. Mail-order pharmacies run by ...

Humana has completed its acquisition of Kindred at Home, the insurer announced late Tuesday. With the deal finished, Humana is now the country's largest provider of home healthcare services. Kindred ...